



February 16, 2017

## **Alder BioPharmaceuticals to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial and Operating Results**

BOTHELL, Wash., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its fourth quarter and full year 2016 financial and operating results after the close of U.S. financial markets on Thursday, February 23, 2017. Alder management will host a conference call and live audio webcast to discuss the results and provide a general business update at 5:00 p.m. ET the same day.

The live call may be accessed by dialing (877) 430-4657 for domestic callers or (484) 756-4339 for international callers, and providing conference ID number 60771333. The webcast will be broadcast live and may be accessed from the Events & Presentations page in the Investors section of Alder's website at [www.alderbio.com](http://www.alderbio.com). A replay will be available following the call for 30 days.

### **About Alder BioPharmaceuticals**

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit <http://www.alderbio.com>.

#### Media Contacts:

David Schull or Victoria Meissner  
Russo Partners, LLC  
(212) 845-4271  
(646) 942-5627  
[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)  
[victoria.meissner@russopartnersllc.com](mailto:victoria.meissner@russopartnersllc.com)

#### Investor Relations Contact:

David Walsey  
Alder BioPharmaceuticals Inc.  
(425) 408-8032  
[ir@alderbio.com](mailto:ir@alderbio.com)